Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 17

1.

NMDA receptor antagonists augment antidepressant-like effects of lithium in the mouse forced swimming test.

Ghasemi M, Raza M, Dehpour AR.

J Psychopharmacol. 2010 Apr;24(4):585-94. doi: 10.1177/0269881109104845. Epub 2009 Apr 7.

PMID:
19351802
2.

[Receptor antagonist of NMDA and animal models of schizophrenia].

Bian SZ, Zhang J, Liu WL, Sun ZH, Gu ZL, Jiang XG.

Fa Yi Xue Za Zhi. 2009 Dec;25(6):443-6. Review. Chinese.

PMID:
20225623
3.

Investigational NMDA receptor modulators for depression.

Szewczyk B, Pałucha-Poniewiera A, Poleszak E, Pilc A, Nowak G.

Expert Opin Investig Drugs. 2012 Jan;21(1):91-102. doi: 10.1517/13543784.2012.638916. Epub 2011 Nov 21. Review.

PMID:
22097925
4.

How does ketamine elicit a rapid antidepressant response?

Kavalali ET, Monteggia LM.

Curr Opin Pharmacol. 2015 Feb;20:35-9. doi: 10.1016/j.coph.2014.11.005. Epub 2014 Nov 25. Review.

5.

NMDA receptor antagonists and pain: ketamine.

Muir WW.

Vet Clin North Am Equine Pract. 2010 Dec;26(3):565-78. doi: 10.1016/j.cveq.2010.07.009. Review.

PMID:
21056300
6.

NMDA antagonists under investigation for the treatment of major depressive disorder.

Pochwat B, Pałucha-Poniewiera A, Szewczyk B, Pilc A, Nowak G.

Expert Opin Investig Drugs. 2014 Sep;23(9):1181-92. doi: 10.1517/13543784.2014.918951. Epub 2014 May 12. Review. Erratum in: Expert Opin Investig Drugs. 2014 Oct;23(10):1457.

PMID:
24818801
7.

A neurotrophic hypothesis of depression: role of synaptogenesis in the actions of NMDA receptor antagonists.

Duman RS, Li N.

Philos Trans R Soc Lond B Biol Sci. 2012 Sep 5;367(1601):2475-84. doi: 10.1098/rstb.2011.0357. Review.

8.

The role of mTOR in depression and antidepressant responses.

Abelaira HM, Réus GZ, Neotti MV, Quevedo J.

Life Sci. 2014 Apr 17;101(1-2):10-4. doi: 10.1016/j.lfs.2014.02.014. Epub 2014 Feb 25. Review.

PMID:
24582593
9.

[Antidepressant effect of ketamine, a N-methyl-D-aspartate (NMDA) glutamate receptor antagonist, in the therapy of treatment-resistant depression].

Gosek P, Chojnacka M, Bieńkowski P, Swiecicki Ł.

Psychiatr Pol. 2012 Mar-Apr;46(2):283-94. Review. Polish.

PMID:
23214398
10.

Ketamine and phencyclidine: the good, the bad and the unexpected.

Lodge D, Mercier MS.

Br J Pharmacol. 2015 Sep;172(17):4254-76. doi: 10.1111/bph.13222. Epub 2015 Jul 28. Review.

PMID:
26075331
11.

Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.

Niciu MJ, Henter ID, Luckenbaugh DA, Zarate CA Jr, Charney DS.

Annu Rev Pharmacol Toxicol. 2014;54:119-39. doi: 10.1146/annurev-pharmtox-011613-135950. Review.

12.

Is there anything really novel on the antidepressant horizon?

Murrough JW, Charney DS.

Curr Psychiatry Rep. 2012 Dec;14(6):643-9. doi: 10.1007/s11920-012-0321-8. Review.

13.
14.

GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists.

Moskal JR, Burch R, Burgdorf JS, Kroes RA, Stanton PK, Disterhoft JF, Leander JD.

Expert Opin Investig Drugs. 2014 Feb;23(2):243-54. doi: 10.1517/13543784.2014.852536. Epub 2013 Nov 20. Review.

15.

The NMDA receptor as a therapeutic target in major depressive disorder.

Pittenger C, Sanacora G, Krystal JH.

CNS Neurol Disord Drug Targets. 2007 Apr;6(2):101-15. Review.

PMID:
17430148
16.

Ketamine as a novel antidepressant: from synapse to behavior.

Murrough JW.

Clin Pharmacol Ther. 2012 Feb;91(2):303-9. doi: 10.1038/clpt.2011.244. Epub 2011 Dec 28. Review.

17.

Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders?

Sanacora G, Schatzberg AF.

Neuropsychopharmacology. 2015 Jan;40(2):259-67. doi: 10.1038/npp.2014.261. Epub 2014 Sep 26. Review. Erratum in: Neuropsychopharmacology. 2015 Apr;40(5):1307.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk